Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 He will also establish a U.S. clinical and research site to complement the company's research capabilities in Shanghai and the U.K. SHANGHAI and LONDON and SOMERVILLE, Mass., Oct....
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) will present results from multiple clinical studies at the congress, including data from its...
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis showed 50% complete corneal healing in the highest dose cohort after an 8-week course HT006.2.2 is designed to offer...
ELEHEAR Earns Two 2026 Hearing Technology Innovator Awards™ from Hearing Health & Technology Matters
Beyond 2 Pro and ElePro® Plus awarded industry recognition as ELEHEAR continues its mission to make personalized hearing care more accessible CHICAGO, Oct. 13, 2026 /PRNewswire/ -- ELEHEAR, a company specializing in AI-powered hearing solutions, has been named a two-time winner of the 2026 Hearing Technology Innovator Awards™, with its Beyond 2 Pro OTC hearing aids and ElePro® Plus tele-audiology...
The Right Doctor Isn’t Always One Doctor
Why complex brain and spine conditions increasingly call for specialists to work across disciplines. KUALA LUMPUR, Malaysia, Oct. 13, 2026 /PRNewswire/ -- When faced with a brain, spine or neurological condition, one of the first questions a patient or family member may ask is: Which doctor should we see? A neurologist? A neurosurgeon? A spine...
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform. ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue and is a...
NOVI Health expands its longevity offering and grows its physician-led team
Longevity Core and Signature offer a structured path from assessment to action SINGAPORE, Oct. 13, 2026 /PRNewswire/ -- NOVI Health announced an expanded Longevity offering anchored by Longevity Core and Longevity Signature (with Interventions), from S$1200. NOVI is also growing its physician team, with Dr Calida Chua joining from the beginning of November 2026. As Singapore's population ages,...
World Thrombosis Day campaign urges global action to protect women against blood clots
Global campaign brings together partners to raise awareness of women's unique blood clot risks, recognize warning signs and take action to prevent life-threatening events. CHARLOTTE, N.C., Oct. 13, 2026 /PRNewswire/ -- One in four people worldwide die from conditions caused by thrombosis, yet blood clots remain among the most overlooked and...
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention...
GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration
Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 13, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that it signed a Memorandum of Understanding (MOU) with LabConnect...
